SecBot SecBot
DEFA14A ·Filed Apr 23, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-173686
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the company's next 10-Q filing for any updates on financial performance or guidance, as this proxy statement contains no new financial information.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$59.49
T+0 close · Apr 23, 2026 · via day close
Latest settled
−2.44%
T+60 · $58.04
Vs SPY
−7.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $59.49entry
  2. T+1 · 7mo ago +0.39%α +0.22% · $59.72
  3. T+5 · 7mo ago −3.78%α −4.69% · $57.24
  4. T+20 · 6mo ago −20.34%α −24.37% · $47.39
  5. T+60 · 4mo ago −2.44%α −7.52% · $58.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15, 2026. The meeting will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation. The filing is routine and does not contain any material financial data or significant corporate actions.

Key Financial Metrics

Vote
director election
Meeting
2026-06-15

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
  • The meeting will be held on June 15, 2026.
  • Proposals include the election of three Class III directors: Olivier Brandicourt, Halley Gilbert, and Grant E. Pickering.
  • The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 will be ratified.
  • The compensation of the named executive officers will be approved on an advisory basis.
  • The Board recommends voting 'For' on all proposals.
  • The filing is routine and does not contain any material financial data or significant corporate actions.

Financial Impact

No material financial impact. The filing is a routine administrative document.

Risk Factors

  • The lack of new financial information or strategic updates in the filing means investors must wait for the next quarterly report for material updates.
  • The advisory vote on executive compensation could be a point of contention for shareholders, although it is non-binding.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-173686
Document: 0001193125-26-173686-index-headers.html0001193125-26-173686
Document: 0001193125-26-173686-index.html0001193125-26-173686
Document: 0001193125-26-173686.txt0001193125-26-173686

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026